Objectives: A non-clinical study was performed to establish a LC-MS/MS method to determine the in vivo active components of doxorubicin hydrochloride liposome injection in the plasma of Sprague-Dawley rats. Methods: T...Objectives: A non-clinical study was performed to establish a LC-MS/MS method to determine the in vivo active components of doxorubicin hydrochloride liposome injection in the plasma of Sprague-Dawley rats. Methods: Ten male SD rats were administered tail vein with a single dose of 10 mg/kg, and the concentrations of doxorubicin hydrochloride in plasma, heart, liver, spleen, lung, and kidney were determined by liquid chromatography-tandem mass spectrometry, and the pharmacokinetic parameters were calculated. Results: The final concentration of doxorubicin hydrochloride ranged from 500 ng/mL to 250,000 ng/mL, and the lower limit of quantification was 500 ng/mL;the main pharmacokinetic parameters: T<sub>1/2</sub> was (19.282 ± 10.305) h, C<sub>max</sub> was (118514.828 ± 26155.134) ng/mL, AUC<sub>0-24</sub> and AUC<sub>0-∞</sub> were (1216659.205 ± 192706.268) ng/mL⋅h and (2082244.523 ± 860139.487) ng/mL⋅h, MRT<sub>0-24</sub> and MRT<sub>0-∞</sub> were (9.237 ± 0.423) h and (26.52 ± 14.015) h, respectively, and clearance (CL) was (0.005 ± 0.002) mL/h⋅ng. Conclusions: The method is simple, rapid, and sensitive, which can be used for the determination of doxorubicin hydrochloride concentration in the plasma of SD rats and pharmacokinetic non-clinical studies.展开更多
本试验制备了载盐酸曲美他嗪(1)的2种缓释制剂,分别是采用湿法制粒制备的缓释片剂和基于缓释包衣微丸的胶囊剂,后者是将采用离心造粒法制备的1缓释包衣微丸灌装而得。以体外释放度为指标,利用星点设计-效应面法优化了微丸包衣材料中Eudr...本试验制备了载盐酸曲美他嗪(1)的2种缓释制剂,分别是采用湿法制粒制备的缓释片剂和基于缓释包衣微丸的胶囊剂,后者是将采用离心造粒法制备的1缓释包衣微丸灌装而得。以体外释放度为指标,利用星点设计-效应面法优化了微丸包衣材料中Eudragit NE 30D与羟丙甲纤维素的比例及包衣增重。以原研1缓释片(Vasorel MR)为参比,对比了2种自制缓释剂型在水、0.1 mol/L盐酸、p H 4.5乙酸盐缓冲液和p H 6.8磷酸盐缓冲液中释放曲线的相似性。结果显示,2种自制品与原研缓释片在4种介质中的释放行为相似。Beagle犬体内药动学研究结果显示,1缓释片和缓释胶囊相对于原研1缓释片的口服生物利用度为(96.8±15.9)%和(101.5±16.7)%。展开更多
文摘Objectives: A non-clinical study was performed to establish a LC-MS/MS method to determine the in vivo active components of doxorubicin hydrochloride liposome injection in the plasma of Sprague-Dawley rats. Methods: Ten male SD rats were administered tail vein with a single dose of 10 mg/kg, and the concentrations of doxorubicin hydrochloride in plasma, heart, liver, spleen, lung, and kidney were determined by liquid chromatography-tandem mass spectrometry, and the pharmacokinetic parameters were calculated. Results: The final concentration of doxorubicin hydrochloride ranged from 500 ng/mL to 250,000 ng/mL, and the lower limit of quantification was 500 ng/mL;the main pharmacokinetic parameters: T<sub>1/2</sub> was (19.282 ± 10.305) h, C<sub>max</sub> was (118514.828 ± 26155.134) ng/mL, AUC<sub>0-24</sub> and AUC<sub>0-∞</sub> were (1216659.205 ± 192706.268) ng/mL⋅h and (2082244.523 ± 860139.487) ng/mL⋅h, MRT<sub>0-24</sub> and MRT<sub>0-∞</sub> were (9.237 ± 0.423) h and (26.52 ± 14.015) h, respectively, and clearance (CL) was (0.005 ± 0.002) mL/h⋅ng. Conclusions: The method is simple, rapid, and sensitive, which can be used for the determination of doxorubicin hydrochloride concentration in the plasma of SD rats and pharmacokinetic non-clinical studies.
文摘本试验制备了载盐酸曲美他嗪(1)的2种缓释制剂,分别是采用湿法制粒制备的缓释片剂和基于缓释包衣微丸的胶囊剂,后者是将采用离心造粒法制备的1缓释包衣微丸灌装而得。以体外释放度为指标,利用星点设计-效应面法优化了微丸包衣材料中Eudragit NE 30D与羟丙甲纤维素的比例及包衣增重。以原研1缓释片(Vasorel MR)为参比,对比了2种自制缓释剂型在水、0.1 mol/L盐酸、p H 4.5乙酸盐缓冲液和p H 6.8磷酸盐缓冲液中释放曲线的相似性。结果显示,2种自制品与原研缓释片在4种介质中的释放行为相似。Beagle犬体内药动学研究结果显示,1缓释片和缓释胶囊相对于原研1缓释片的口服生物利用度为(96.8±15.9)%和(101.5±16.7)%。